January 28, 2017
Swedish Vicore Pharma’s IPF candidate C21 becomes orphan drug in US
Vicore Pharma’s C21 drug for treating idiopathic pulmonary fibrosis (IPF) has officially became an orphan drug in the USA.
Pharmaceuticals, Biotechnology and Life Sciences
Vicore Pharma’s C21 drug for treating idiopathic pulmonary fibrosis (IPF) has officially became an orphan drug in the USA.